Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.

Wright GEB, Collins JA, Kay C, McDonald C, Dolzhenko E, Xia Q, Bečanović K, Drögemöller BI, Semaka A, Nguyen CM, Trost B, Richards F, Bijlsma EK, Squitieri F, Ross CJD, Scherer SW, Eberle MA, Yuen RKC, Hayden MR.

Am J Hum Genet. 2019 Jun 6;104(6):1116-1126. doi: 10.1016/j.ajhg.2019.04.007. Epub 2019 May 16.

PMID:
31104771
2.

Patient perspectives on the process and outcomes of psychiatric genetic counseling: An "Empowering Encounter".

Semaka A, Austin J.

J Genet Couns. 2019 Aug;28(4):856-868. doi: 10.1002/jgc4.1128. Epub 2019 May 3.

PMID:
31050075
3.

The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population.

Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, Greenberg JL, Krause A, Hayden MR.

Am J Med Genet B Neuropsychiatr Genet. 2018 Apr;177(3):346-357. doi: 10.1002/ajmg.b.32618. Epub 2018 Feb 20.

PMID:
29460498
4.

Women's experiences of participating in a prospective, longitudinal postpartum depression study: insights for perinatal mental health researchers.

Andrighetti HJ, Semaka A, Austin JC.

Arch Womens Ment Health. 2017 Aug;20(4):547-559. doi: 10.1007/s00737-017-0744-7. Epub 2017 Jun 10.

5.

Pharmacokinetics of Short- and Long-acting Formulations of Oxytetracycline After Intramuscular Administration in Chickens.

Gberindyer AF, Okpeh ER, Semaka AA.

J Avian Med Surg. 2015 Dec;29(4):298-302. doi: 10.1647/2015-076.

PMID:
26771319
6.

Obsessive-Compulsive Disorder: The Process of Parental Adaptation and Implications for Genetic Counseling.

Andrighetti H, Semaka A, Stewart SE, Shuman C, Hayeems R, Austin J.

J Genet Couns. 2016 Oct;25(5):912-22. doi: 10.1007/s10897-015-9914-9. Epub 2015 Dec 7.

7.

A new mutation for Huntington disease following maternal transmission of an intermediate allele.

Semaka A, Kay C, Belfroid RD, Bijlsma EK, Losekoot M, van Langen IM, van Maarle MC, Oosterloo M, Hayden MR, van Belzen MJ.

Eur J Med Genet. 2015 Jan;58(1):28-30. doi: 10.1016/j.ejmg.2014.11.005. Epub 2014 Nov 20.

PMID:
25464109
8.

Conceptualizing genetic counseling as psychotherapy in the era of genomic medicine.

Austin J, Semaka A, Hadjipavlou G.

J Genet Couns. 2014 Dec;23(6):903-9. doi: 10.1007/s10897-014-9728-1. Epub 2014 May 21.

9.

Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results.

Semaka A, Hayden MR.

Clin Genet. 2014 Apr;85(4):303-11. doi: 10.1111/cge.12324. Epub 2014 Jan 15. Review.

PMID:
24256063
10.

High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population.

Semaka A, Kay C, Doty CN, Collins JA, Tam N, Hayden MR.

Am J Med Genet B Neuropsychiatr Genet. 2013 Dec;162B(8):864-71. doi: 10.1002/ajmg.b.32193. Epub 2013 Aug 30.

PMID:
24038799
11.

De novo Huntington disease caused by 26-44 CAG repeat expansion on a low-risk haplotype.

Houge G, Bruland O, Bjørnevoll I, Hayden MR, Semaka A.

Neurology. 2013 Sep 17;81(12):1099-100. doi: 10.1212/WNL.0b013e3182a4a4af. Epub 2013 Aug 14. No abstract available.

12.

CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease.

Semaka A, Kay C, Doty C, Collins JA, Bijlsma EK, Richards F, Goldberg YP, Hayden MR.

J Med Genet. 2013 Oct;50(10):696-703. doi: 10.1136/jmedgenet-2013-101796. Epub 2013 Jul 29.

PMID:
23896435
13.

Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes.

Baine FK, Kay C, Ketelaar ME, Collins JA, Semaka A, Doty CN, Krause A, Greenberg LJ, Hayden MR.

Eur J Hum Genet. 2013 Oct;21(10):1120-7. doi: 10.1038/ejhg.2013.2. Epub 2013 Mar 6.

14.

"Grasping the grey": patient understanding and interpretation of an intermediate allele predictive test result for Huntington disease.

Semaka A, Balneaves LG, Hayden MR.

J Genet Couns. 2013 Apr;22(2):200-17. doi: 10.1007/s10897-012-9533-7. Epub 2012 Aug 18.

PMID:
22903792
15.

When they hear what we say: ethical challenges in presenting research findings to the Huntington disease community.

Bombard Y, Cox SM, Semaka A.

J Empir Res Hum Res Ethics. 2011 Sep;6(3):47-54. doi: 10.1525/jer.2011.6.3.47.

PMID:
21931237
16.

Adoption and the communication of genetic risk: experiences in Huntington disease.

Bombard Y, Semaka A, Hayden MR.

Clin Genet. 2012 Jan;81(1):64-9. doi: 10.1111/j.1399-0004.2010.01614.x. Epub 2011 Jan 9.

PMID:
21204796
17.

Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles).

Semaka A, Collins JA, Hayden MR.

Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):314-20. doi: 10.1002/ajmg.b.30970.

PMID:
19455596
18.

CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup.

Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR.

Am J Hum Genet. 2009 Mar;84(3):351-66. doi: 10.1016/j.ajhg.2009.02.003. Epub 2009 Feb 26.

19.

Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats.

Semaka A, Warby S, Leavitt BR, Hayden MR.

Mov Disord. 2008 Sep 15;23(12):1794-5; author reply 1793. doi: 10.1002/mds.21820. No abstract available.

PMID:
18548612
20.

Predictive testing for Huntington disease: interpretation and significance of intermediate alleles.

Semaka A, Creighton S, Warby S, Hayden MR.

Clin Genet. 2006 Oct;70(4):283-94. Review. Erratum in: Clin Genet. 2007 Jan;71(1):99.

PMID:
16965319

Supplemental Content

Loading ...
Support Center